POTENTIAL DRUG INTERACTIONS IN PARTICIPANTS OF A HEALTH EDUCATION PROGRAM, PRESENTING TYPE 2 DIABETIC
Abstract
Cross-sectional study in order to determine the prevalence, clinical impact and factors associated with Potential Drug
Interactions (PDI) in participants with type 2 diabetes (DM2) of a health education program. This study involved 71
diabetics grouped according to the presence or absence of PDI and data were obtained individually by a semi-structured
questionnaire. PDI were classified using the UpToDate® database and the participants were compared according to
socio-demographic and clinical variables through chi-square and t student tests. Each participant used 4.6 drugs
on average and over 70% of participants showed some PDI (total of 140 interactions). Over 70% of them required
monitoring of pharmacotherapy and 6.4% of them would need to consider a change in therapy. PDI increased with
the number of drugs prescribed (p<0.001) and did not change according to the gender, age and duration of DM2
Keywords
Full Text:
PDF (Português (Brasil))DOI: http://dx.doi.org/10.14450/2318-9312.v27.e3.a2015.pp160-167
Refbacks
- There are currently no refbacks.
Copyright (c) 2015 Infarma - Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Infarma - Ciências Farmacêuticas
ISSN - 2318-9312 (Versão eletrônica)
ISSN - 0104-0219 (Versão impressa)
Conselho Federal de Farmácia - CFF
SHIS QI 15 Lote "L" - Lago Sul - Brasília - DF
CEP: 71635-615 - Fone: (61)3878-8751
e-mail:infarma@cff.org.br
Diretoria
Walter da Silva Jorge João, Presidente do Conselho Federal de Farmácia
Lenira da Silva Costa, Vice-Presidente do Conselho Federal de Farmácia
João Samuel de Morais Meira, Tesoureiro do Conselho Federal de Farmácia
Luiz Gustavo de Freitas Pires, Secretário-Geral do Conselho Federal de Farmácia